Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
"Alirocumab is the first nonstatin that appears to reduce additional cardiovascular events on top of statin therapy, and this is very encouraging since previous trials of various lipid-lowering and other drugs have failed to find this,” said principal investigator Jennifer Robinson, MD, from the University of Iowa, Iowa City, IA, in the USA.
“Given the data available, alirocumab should prove a useful addition for lowering low density lipoprotein cholesterol (LDL-C) in high risk patients, including those with genetic high cholesterol or who cannot tolerate the recommended dose of statin.”
“We still need to see the results of the ongoing long-term cardiovascular outcomes trial to determine whether alirocumab should be routinely added to statin therapy to further reduce cardiovascular risk in high risk patients,” noted Dr. Robinson.
© 2017 European Society of Cardiology. All rights reserved